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ABSTRACT 
Objectives: In recent years, a sharp increase has been noted 
in The E. Wolfson Hospital, Holon, Israel, in the isolation rate 
of enterococci from urine samples. The purpose of the study 
was to examine whether this phenomenon was associated with 
a change in antibiotic use in the institution. 
Methods: The isolation rate of enterococci from urine samples 
and the amount of fluoroquinolones and cephalosporins utilized 
in three periods during 1987, 1990, and 1993 were calculated. 
Results: Fluoroquinolones were introduced in The E. Wolfson 
Hospital in 1988. Between 1990 and 1993, both the use of 
fluoroquinolones and the isolation of enterococci increased 
by 50%. No change in the use of cephalosporins was observed 
during the same period. 
Conc/usions: The effect of the extensive use of fluoroquinolones 
on colonization by, and superinfection with enterococci is 
explained by the broad antibacterial spectrum of these agents 
on one hand and their mediocre in vitro activity against entero- 
cocci on the other. This association is particularly worrisome 
since it may contribute indirectly to the spread of vancomycin- 
resistant enterococci. 
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For many years, enterococci were considered minor 
pathogens that were relatively avirulent in healthy indi- 
viduals. As natural inhabitants of the gastrointestinal tract 
and the female genital tract, they caused urinary tract 
infections, mainly in catheterized patients; however, their 
role in the pathogenesis of intra-abdominal infections was 
a controversial subject. In the past decade enterococci 
have emerged as dominant nosocomial pathogens. 
Indeed, they are now the second most frequently isolated 
nosocomial pathogen overall, the second most common 
nosocomial urinary isolate, and the third leading cause of 
nosocomial bacteremia.‘J Moreover, epidemiologic stud- 
ies have shown that enterococcal infections can be 
caused not only by the patients’ endogenous flora but 
also as a consequence of intrahospital and interhospital 
spread.3 The emergence of enterococci as common noso- 
comial pathogens is particularly worrisome because of 
the appearance and increasing prevalence of vancomycin 
resistance among these organisms.4 
Both the accelerated emergence of enterococci as 
nosocomial pathogens and the development of van- 
comycin resistance have been attributed mainly to the 
widespread use of antimicrobials lacking enterococcal 
activity, such as the cephalosporins.5 To learn more about 
this phenomenon, the authors investigated the relation 
between the increase of enterococcal isolation from urine 
samples and the use of newer antimicrobial agents in an 
acute care general hospital. 
MATERIAL AND METHODS 
The study was carried out in The E. Wolfson Hospital, a 
600 bed general hospital in the greater Tel Aviv area of 
Israel. The hospital serves a population of 440,000. The 
microbiology laboratory records were used to enumerate 
the urine samples submitted for culture and those from 
which enterococci were isolated (one isolate per patient). 
Three periods were studied: 1987, 1990, and 1993. Data 
on the amount of fluoroquinolones (ciprofloxacin, nor- 
floxacin, and ofloxacin) and cephalosporins (cefazolin, 
cefuroxime, cefonicid, cefotaxime, ceftriaxone, and cef- 
tazidime) used in the hospital during the corresponding 
years were provided by the hospital pharmacy service. 
The usage of these agents was calculated in grams per 
1000 admissions. For statistical analysis, the chi-square 
test was used. 
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RESULTS 
The rate of isolation of enterococci per 1000 urine sam- 
ples submitted for culture and the amount of fluoro- 
quinolones and cephalosporins consumed in the periods 
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studied are presented in Table 1. Whereas the entero- 
coccal isolation rate and the amount of fluoroquinolones 
consumed have increased over the years (P < O.OOl), no 
change in the use of cephalosporins was noted. Aztre- 
onam, another new antibiotic that lacks anti-enterococ- 
cal activity, is rarely used at The E. Wolfson Hospital 
(about 6 g/1000 patients were prescribed in 1993). 
DISCUSSION 
The fluoroquinolones were introduced in The E. Wolf- 
son Hospital in 1988. Interestingly, the increment of both 
fluoroquinolone consumption and enterococcal isolation 
rate between 1990 and 1993 were similar (-50%). The 
possibility of an association between these two trends is 
increased by the fact that during the same period use of 
cephalosporins, the antibiotic group most often impli- 
cated in enterococcal superinfection, was stable. Among 
other recently introduced antibiotic groups, such as 
monobactams and carbapenems, only the former may 
select for enterococcal superinfection. The use of aztre- 
onam at The E. Wolfson Hospital during the relevant 
period was negligible. Moreover, the authors are not 
aware of any other relevant factors, such as introduction 
of a new procedure, change in the composition of hos- 
pitalized patient population, or change in the duration of 
hospitalization, that might have contributed to the 
increase in enterococcal isolation rate. 
The role of the extensive use of cephalosporins as a 
risk factor for acquisition of, and superinfection with, ente- 
rococci has been well documented.lJ-* Previously uncom- 
mon enterococcal infections, such as pneumonias, have 
become more common with the increased use of third- 
generation cephalosporins8 Indeed, although cephalo- 
sporins exhibit a broad spectrum of antibacterial activity, 
they are inherently inactive against enterococci. Thus, by 
suppressing the growth of other components of the 
normal flora, they favor enterococcal colonization and 
infection. l 
That a similar phenomenon would be observed with 
the introduction of fluoroquinolones could have been sug- 
gested by the mediocre in vitro activity of these com- 
pounds against enterococci.9 Enterococci are the least 
susceptible gram-positive organisms to fluoroquinolones 
with minimum inhibitory concentrations of different agents 
ranging between 4.0 and 16.0 ug/mL.9 Between 1987 and 
1991, the percentage of ciprofloxacin-susceptible entero- 
cocci in a medical center in Minneapolis, Minnesota, USA, 
dropped from 98% to 62%.” In studies evaluating the 
impact of fluoroquinolones on gastrointestinal flora, admin- 
istration of these agents was associated with an increase 
in the carriage rate of Enterococcus faeciwm1’J2 
Several reports have documented enterococcal super- 
infection in patients treated with fluoroquinolones.13-15 
Table 1. Rate of Isolation of Enterococci from Urine 
Samples and Consumption of Antimicrobials 
in The E. Wolfson Hospital, Holon, Israel 
Year 
1987 1990 1993 
Enterococcal isolates/i 000 urine 
samples cultured (n) 
Fluoroquinolones/lOOO patients (g) 
Cephalosporins/lOOO patients (g) 
15 23 33 
0 220 313 
1972 1472 1642 
Among 32 patients treated with ciprofloxacin for urinary 
tract infections, superinfection occurred in eight (25%); 
Candida spp caused superinfection in four patients 
(13%) and enterococcal superinfection was documented 
in three (10%).i3 A similar rate of enterococcal superin- 
fection in patients treated with ciprofloxacin for urinary 
tract infection was noted by Goldstein et al.l* Zevros et 
al have shown that the apparent bactericidal effect of 
quinolones against enterococci may be inoculum depen- 
dent, at least in some strains.‘j In two patients with ente- 
rococcal superinfection following therapy with 
ciprofloxacin, the strains were susceptible to low con- 
centrations of the quinolone when tested at a standard 
inoculum. However, at an inoculum of 1 X 10’ colony- 
forming units (CFU)/mL, they showed resistance to high 
concentrations of the drug. Thus, it is not surprising that 
the increase in isolation rate of enterococci from urine 
samples in the hospital correlated with the mounting 
consumption of fluoroquinolones. With fluoroquinolones 
and trimethoprim-sulfamethoxazole considered as the 
drugs of choice for treatment of urinary tract infections, 
this phenomenon is expected to continue to grow. Its 
possible indirect impact on the spread of vancomycin- 
resistant enterococci is particularly worrisome. Priority 
should be given to the consideration of strategies to min- 
imize this adverse effect of fluoroquinolones on hospital 
microbial ecology. 
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